Which of the following is a specific cost to be considered for a CLIA-waived test?

When evaluating the costs associated with a CLIA-waived test, it is essential to identify test-specific costs, as these directly pertain to the testing process and the resources required to perform that particular test. This includes the price of the test kits, quality control materials, reagents, and other consumables that are essential to conducting the test accurately and in compliance with regulatory standards.

Costs like training expenses, while important for overall operational readiness, do not pertain exclusively to the specific test being conducted. Patient follow-up costs are typically related to managing patient care after testing and do not account for the direct costs associated with performing the test itself. Marketing expenses, meanwhile, focus on promoting the service and are not typically linked to the operational costs of conducting CLIA-waived tests.

Therefore, by focusing on test-specific costs, one can adequately assess the financial implications of implementing and maintaining those tests in a healthcare setting, ensuring both quality patient care and compliance with regulatory guidelines.